FDA warns of heart risk with HIV drug combination

Oct 21, 2010

(AP) -- The Food and Drug Administration is warning HIV patients not to combine two widely used antiviral drugs because they can cause dangerous heart rhythms.

The agency says the combination of Roche's Invirase and Abbott Laboratories' Norvir can trigger irregular heartbeats, leading to fainting, lightheadedness and even death. The FDA is requiring the companies to add information about the risk to their drugs' warning labels and to distribute pamphlets to patients.

Patients with HIV generally cycle through combinations of medicines to control the virus, which attacks the immune system.

The FDA approved Invirase in 1995 to lower HIV levels in the blood. It is often combined with Norvir to improve its effectiveness.

More than 1.1 million people in the U.S. have , according to the Centers for Disease Control and Prevention.

Explore further: WHO: Millions of Ebola vaccine doses ready in 2015

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA approves antiretroviral drug

Aug 07, 2007

The U.S. Food and Drug Administration has approved the antiretroviral drug maraviroc for use in adult human immunodeficiency virus patients.

FDA orders new Nonoxynol-9 warning

Dec 18, 2007

The U.S. Food and Drug Administration issued a final rule Tuesday requiring manufacturers of nonoxynol-9, or N9, to add a warning to the product's label.

FDA OKs 50th & 51st anti-retroviral drugs

Aug 14, 2007

The U.S. Food and Drug Administration has tentatively approved nevirapine tablets and a pediatric medication used to treat the human immunodeficiency virus.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

5 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0